Selloff in crypto is creating fears that go beyond crypto, says Cantor Fitzgerald's C.J. Muse

C.J. Muse, Cantor Fitzgerald senior analyst, joins 'The Exchange' to discuss Muse's thoughts on Thursday's selloff, Nvidia's ...

Palo Alto Networks Called A 'Buy' On The Dip, Analysts Bet On Its AI Security Lead

Palo Alto Networks (PANW) is dominating the AI-era cybersecurity market through strategic acquisitions and platform expansion ...

Cantor Fitzgerald Sticks to Its Buy Rating for NETSTREIT (NTST)

Cantor Fitzgerald analyst Jay Kornreich maintained a Buy rating on NETSTREIT today and set a price target of $21.00. The company’s shares closed today at $18.62. Take advantage of TipRanks Premium at ...
TipRanks on MSN

Lexeo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Lexeo Therapeutics (LXEO) with an Overweight rating and $19 price target Lead asset LX2006 is an ...

Cantor Fitzgerald Boosts Tesla (TSLA) Price Target as New Production Plans Accelerate Growth Outlook

Tesla Inc. (NASDAQ:TSLA) ranks among the best sustainability stocks to invest in. On October 27, Cantor Fitzgerald maintained ...

Cantor Fitzgerald Raises the PT on nLIGHT, Inc. (LASR), Keeps a Buy

LIGHT, Inc. (NASDAQ:LASR) is one of the Hottest Small Cap Stocks to Buy Now. On November 7, Cantor Fitzgerald analyst Troy ...

Cantor Fitzgerald Sticks to Its Hold Rating for Cartesian Therapeutics (RNAC)

Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.
Le Lézard

Securitize and Cantor Equity Partners II Announce Confidential Submission of Draft Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission

Securitize, Inc. ("Securitize" or the "Company"), the world's leading platform1 for tokenizing real-world assets, and Cantor Equity Partners II, Inc. ("CEPT"), a special purpose acquisition company ...

Cantor Fitzgerald Reaffirms Price Target on Eli Lilly (LLY) Despite GLP-1 Setback

Eli Lilly & Company (NYSE:LLY) ranks among the stocks with the best earnings growth for the next 5 years. Cantor Fitzgerald reaffirmed its Overweight rating and $925 price target for Eli Lilly & ...